HRPC(SH:600829) Shang Hai Zheng Quan Bao·2025-11-12 18:06Core Viewpoint - The stock of Harbin Pharmaceutical Group People's Tongtai Pharmaceutical Co., Ltd. has experienced significant price fluctuations, with a cumulative increase of over 20% in three consecutive trading days, indicating abnormal trading conditions [2][3][4]. Group 1: Stock Performance - The company's stock price increased significantly on November 7, 10, and 11, 2025, with a cumulative closing price deviation exceeding 20%, classified as abnormal trading behavior according to Shanghai Stock Exchange rules [2][3][4]. - On November 12, 2025, the company's stock hit the daily limit again, reflecting a substantial short-term price increase [2][3]. Group 2: Financial Metrics - As of November 11, 2025, the company's rolling price-to-earnings (P/E) ratio was 55.29, significantly higher than the industry average P/E ratio of 18.43 for the "pharmaceutical commerce" sector [2][4]. - For the first three quarters of 2025, the company reported revenue of 784,592.89 million yuan, a year-on-year increase of 2.19%, while the net profit attributable to shareholders was 11,187.65 million yuan, reflecting a year-on-year decline of 45.69% [2][5]. Group 3: Business Operations - The company's main business activities, which include pharmaceutical wholesale, retail, logistics services, and medical services, have not undergone significant changes, and operations remain normal [3]. Group 4: Market Sentiment - The company has not identified any media reports or market rumors that require clarification or response, indicating a stable perception in the market [6][7]. - The company has confirmed that there are no undisclosed significant events that could impact stock price fluctuations, such as major asset restructuring or strategic investments [7].